Answers are grounded in this paper and cite their sources.
Tralokinumab 300 mg plus TCS as needed was effective and well tolerated in patients with severe AD whose disease was not adequately controlled with CSA or who had contraindications to oral CSA.
No takes yet. Share an insight, caveat, or question.
Gutermuth et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: